高血栓风险腹部大手术围术期药物预防的最佳时机:多中心队列研究
该多中心队列研究纳入Caprini评分>4的高血栓风险腹部大手术患者,比较早期(关腹前)与术后启动药物预防对静脉血栓栓塞症(VTE)和出血的影响。结果显示两组临床VTE发生率无差异,但早期用药显著增加出血及再干预风险。
要点
- 高血栓风险腹部大手术患者早期药物预防不降低VTE,反而增加出血风险。
- 术后启动药物预防更安全,不增加临床VTE风险。
- 临床决策应权衡血栓与出血风险,倾向术后启动药物预防。
核心结论
- 在高VTE风险腹部大手术患者中,术后启动药物预防可降低出血风险而不影响临床VTE风险。
研究设计与样本
- 研究汇总5项多中心研究数据,仅纳入Caprini评分>4的高血栓风险患者,共5501例。
- 早期(关腹前)药物预防1752例(31.8%),术后药物预防3749例(68.2%)。
主要发现
- 临床VTE发生率早期组0.7% vs 术后组0.7%(OR 1.11,95%CI 0.60-2.15,P=0.730)。
- 所有出血发生率早期组5.1% vs 术后组2.6%(OR 2.04,95%CI 1.52-2.73,P<0.001)。
- 大出血发生率早期组3.6% vs 术后组1.8%(OR 1.99,95%CI 1.40-2.81,P<0.001)。
- 再干预率早期组2.0% vs 术后组1.0%(OR 2.10,95%CI 1.32-3.35,P=0.003)。
- 早期药物预防独立预测术后出血(OR 1.71,95%CI 1.25-2.34,P<0.001),但不预测VTE。
关键数值与推荐
- 高血栓风险定义为Caprini评分>4。
- 临床VTE定义为术后30天内影像学证实的有症状疾病。
- 大出血定义为需要输血、再干预或血红蛋白下降>20 g/L。
临床怎么用
- 对于Caprini评分>4的腹部大手术患者,建议术后启动药物预防而非关腹前早期启动,以降低出血风险且不增加VTE。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether early (before skin closure) versus postoperative chemoprophylaxis affects the incidence of venous thromboembolism (VTE) and bleeding following major abdominal surgery, in a high thromboembolic risk population. BACKGROUND: Major abdominal surgery incurs both VTE and bleeding risks. Patients with high preoperative VTE risk derive the most benefit from chemoprophylaxis, but carry an increased risk of bleeding. The optimal window for chemoprophylaxis in the perioperative period, whereby both VTE and bleeding risks are minimized, is unknown. METHODS: Analysis of pooled data from 5 multicenter studies including only high thromboembolic risk (Caprini score >4) patients. Clinical VTE was defined as radiographically proven symptomatic disease <30 days postsurgery. Major bleeding was defined as the need for blood transfusion, reintervention, or >20 g/L fall in hemoglobin. RESULTS: From 5501 cases, chemoprophylaxis was initiated early in 1752 (31.8%) patients and postoperatively in 3749 (68.2%) patients. Baseline characteristics were similar between study groups. The incidence of clinical VTE was not associated with chemoprophylaxis timing [early 0.7% vs. postop 0.7%, odds ratio (OR): 1.11, 95% confidence interval (CI): 0.60-2.15, P =0.730]. Contrastingly, compared with postoperative chemoprophylaxis, early usage increased the risk of all bleeding (5.1% vs. 2.6%, OR: 2.04, 95% CI: 1.52-2.73, P <0.001) major bleeding (3.6% vs. 1.8%, OR: 1.99, 95% CI: 1.40-2.81, P <0.001), and reintervention (2.0% vs. 1.0%, OR: 2.10, 95% CI: 1.32-3.35, P =0.003). Early chemoprophylaxis independently predicted postoperative bleeding (OR: 1.71, 95% CI: 1.25-2.34, P <0.001), but not VTE. CONCLUSIONS: In high VTE risk patients undergoing major abdominal surgery, chemoprophylaxis commenced postoperatively reduces bleeding risk without affecting clinical VTE risk.
引用
- Liu DS, Stevens SG, Watson DI, et al. Optimal Timing of Perioperative Chemoprophylaxis in Patients With High Thromboembolic Risk Undergoing Major Abdominal Surgery: A Multicenter Cohort Study. Ann Surg. 2022. PMID: 36512695. doi:10.1097/SLA.0000000000005697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。